In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Shionogi To Buy Sciele Of U.S. For $1.4 Billion

This article was originally published in PharmAsia News

Executive Summary

Shionogi of Japan plans to pay $1.4 billion to acquire the U.S. firm Sciele Pharma in a foreign expansion move. The company becomes the latest in a string of Japanese pharmaceutical companies to buy firms abroad as Japan moves to reduce the prices of drugs for its citizens. Based partly on its best-seller drug Crestor (rosuvastatin) for lowering cholesterol, 82 percent of Shionogi's sales currently come from Japan. The purchase would expand the Japanese company's research and development stafff and provide it with its own U.S. sales staff. Shionogi suffered its slowest growth in profit in the first half of this year even though sales increased by 3 percent. (Click here for more
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel